BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 5772094)

  • 1. Control of renin release in experimental hypertension.
    Ayers CR; Harris RH; Lefer LG
    Circ Res; 1969 May; 24(5 Suppl):103-12. PubMed ID: 5772094
    [No Abstract]   [Full Text] [Related]  

  • 2. [Renin and arterial hypertension].
    Schwartz J; Bloch R; Velly J; Imbs JL; Warter J
    Ann Biol Clin (Paris); 1966; 24(10):1049-59. PubMed ID: 5985524
    [No Abstract]   [Full Text] [Related]  

  • 3. Renal vein renin in renovascular hypertension.
    Woods JW; Michelakis AM
    Arch Intern Med; 1968 Nov; 122(5):392-3. PubMed ID: 5687925
    [No Abstract]   [Full Text] [Related]  

  • 4. Effect of reserpine pretreatment on in vivo femoral arterial responses to vasodilator agents.
    Cauvin CA; Devia CJ; Kirkendol PL
    J Pharmacol Exp Ther; 1981 Mar; 216(3):447-52. PubMed ID: 6782236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma renin activity during development of experimental renal hypertension in dogs.
    Basso N; de la Riva IJ; Taquini AC
    Acta Physiol Lat Am; 1974; 24(5):563-8. PubMed ID: 4377509
    [No Abstract]   [Full Text] [Related]  

  • 6. Renin secretion in the patient with hypertension. Relationship to intrarenal blood flow distribution.
    Hollenberg NK; Epstein M; Basch RI; Merrill JP; Hickler RB
    Circ Res; 1969 May; 24(5 Suppl):113-22. PubMed ID: 4890678
    [No Abstract]   [Full Text] [Related]  

  • 7. Angiotensin blocking actions of guancydine.
    Cummings JR; Welter AN; Grace JL; Gray WD
    J Pharmacol Exp Ther; 1969 Dec; 170(2):334-46. PubMed ID: 4311323
    [No Abstract]   [Full Text] [Related]  

  • 8. [Control of hypertension by means of surgical systemic-portal shunt in dogs with experimental bilateral stenosis of the renal arteries].
    Gaspari A; Graziani S; Di Cesare T
    Ann Ital Chir; 1975-1976; 49(1-6):151-61. PubMed ID: 1053134
    [No Abstract]   [Full Text] [Related]  

  • 9. Mechanisms involved in renal hypertension.
    Bianchi G; Fox U; Pagetti D; Caravaggi AM; Baer PG; Baldoli E
    Kidney Int Suppl; 1975 Sep; ():S165-73. PubMed ID: 1104970
    [No Abstract]   [Full Text] [Related]  

  • 10. Chronic hydralazine improves flow (shear stress)-induced endothelium-dependent dilation in mouse mesenteric resistance arteries in vitro.
    Gorny D; Loufrani L; Kubis N; Lévy BI; Henrion D
    Microvasc Res; 2002 Jul; 64(1):127-34. PubMed ID: 12074639
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renin release: effects of vasodilators and bilateral ureteral obstruction.
    Nascimento L; Harris AP; Ayala JM; Opava-Stitzer S; Martinez-Maldonado M
    J Pharmacol Exp Ther; 1980 Mar; 212(3):481-6. PubMed ID: 6987374
    [No Abstract]   [Full Text] [Related]  

  • 12. The influence of calcium on renin release.
    Maull KI; Rees D; Luke R; Kotchen T
    Surg Forum; 1974; 25(0):193-5. PubMed ID: 4439161
    [No Abstract]   [Full Text] [Related]  

  • 13. [Plasmatic concentration of renin in human arterial hypertension].
    Bianchi G; Campolo L; Riva D; Vegeto A
    Minerva Nefrol; 1966; 13(4):119-22. PubMed ID: 5995532
    [No Abstract]   [Full Text] [Related]  

  • 14. Renin, sodium-retaining and sodium-excreting hormones and experimental renal hypertension.
    Davis JO; Howards SS; Johnston CI; Wright FS
    Circ Res; 1967 Jul; 21(1):Suppl 2:167+. PubMed ID: 5599095
    [No Abstract]   [Full Text] [Related]  

  • 15. [Renin in human and experimental renal hypertension].
    Verniory A; Cuykens JJ; Cremer M; Lotteau B; Toussaint C
    Pathol Biol; 1968 May; 16(9):583-6. PubMed ID: 4879109
    [No Abstract]   [Full Text] [Related]  

  • 16. Hydralazine and plasma renin activity.
    Ueda H; Yagi S; Kaneko Y
    Arch Intern Med; 1968 Nov; 122(5):387-91. PubMed ID: 5687924
    [No Abstract]   [Full Text] [Related]  

  • 17. The pathophysiology of renin release in renovascular hypertension.
    Welch WJ
    Semin Nephrol; 2000 Sep; 20(5):394-401. PubMed ID: 11022891
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conditions for enhancement of renin release by isoproterenol, dopamine, and glucagon.
    Holdaas H; Langaard O; Eide I; Kiil F
    Am J Physiol; 1982 Mar; 242(3):F267-73. PubMed ID: 7039349
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antihypertensive and renal protective effects of renin-angiotensin system blockade in uremic rats treated with erythropoietin.
    Lebel M; Rodrigue ME; Agharazii M; Larivière R
    Am J Hypertens; 2006 Dec; 19(12):1286-92. PubMed ID: 17161776
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regional blood flow and cardiac responses to hydralazine.
    Spokas EG; Wang HH
    J Pharmacol Exp Ther; 1980 Feb; 212(2):294-303. PubMed ID: 7351643
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.